we know how
immunostep

TRBC1/TRBC2 double-labeling: accuracy in the identification of T neoplasms by flow cytometry

Characterization of the αβ TCR repertoire at the isoform level by flow cytometry



ADVANTAGES

1. The combined use of anti-TRBC1 and TRBC2 allows the detection of clonal T populations with high accuracy, similar to kappa/lambda analysis in B cells.
2. Fast and reliable detection of T clonalities.
3. Increases diagnostic sensitivity, reduces artifacts of single labeling.
4. Improved quality of analysis, ideal for clinical lab.

Do you want more information?
Scan this QR code and see all the details.

we know how
immunostep
Avda. Universidad de Coimbra, s/n
Cancer Research Center (C.I.C.)
Campus Miguel de Unamuno
37007 Salamanca (Spain)
+34 923 294 827
info@immunostep.com
www.immunostep.com



TCRCB1 and TCRCB2 are mutually exclusive allow clear and non-overlapping gating.



	Median MedFI (min-max)	Ratio (min-max)
Other competitors	50,451 (36,054 - 69,363)	38,49 (13,60 - 40,17)
Immunostep	64,275 (48,566 - 75,822)	58,59 (5,33 - 64,45)

Better performance than other competitors.



Specificity of the TRBC2-PE antibody, distinguishing its background reactivity on non-target cells (TCRγδ or TRBC1-positive target cells (TCRγδ or TRBC1 positive).

- The exclusive use of TRBC1 can induce artifacts ("dim TRBC1"), present in 27% of the samples. Double labeling completely resolves these artifacts and allows a more precise identification of the expressed TRBC isoform.
- Tested in different protocols with optimal performance in all of them: EuroFlow™ FACS Lysis, staining-lysis (NH 4 Cl)-wash, lysis (NH 4 Cl)-staining-wash.
- Evaluated in the basic and extended module T.

Anti-Human TCR Cβ 1 (JOVI-1)

	REF	Σ		[A]	
PURE	JOVIPU	1 mg	1 mg/ml		RUO
FITC	JOVIF	100 test	2 µL/test	0,02 mg/ml	
Dy-634	JOVIDY634	100 test	2 µL/test	0,02 mg/ml	
PE-Cyanine7	JOVIPC7	50 test	3 µL/test	0,03 mg/ml	

Anti- Human T CR Cβ 2 (SAM.2.rMAb)

	REF	Σ		[A]	
PE	TCRCB2PE	100 test	2 µl/ test	0,5 mg/ml	RUO